Corporate, Product

Hikma signs exclusive license agreement with Azanta for Nimoral

London, 26 February 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the signing of an exclusive license agreement with speciality pharmaceutical company Azanta A/S for its proprietary cancer product Nimoral (nimorazole). Nimoral is a hypoxic radiosensitizer to enhance the effect of radiotherapy in head and neck cancer patients. The product is currently in Phase 3 clinical development and is being made available under named patient programs throughout the world.

Under the terms of the agreement, Hikma will have the exclusive rights to register, manufacture, distribute and market Nimoral in 20 markets in the MENA region including Turkey, leveraging Hikma’s strong local presence and regulatory expertise, with over 1,800 sales and marketing reps across the region.

Mazen Darwazah, Hikma’s Vice-Chairman and CEO of MENA and Emerging Markets said, “Hikma is committed to improving the treatment of cancer in the MENA region through the development of our oncology product portfolio.  This partnership gives us access to a novel, oral anticancer treatment with excellent potential and reinforces our commitment to growing our portfolio through strong partnerships.  We look forward to the Phase 3 results for Nimoral and we are very pleased to be working with Azanta to bring this critically needed therapy to the MENA region.”

Dr Claus Møller, Chief Executive Officer of Azanta, commented: "We are very pleased to enter this significant agreement with Hikma.  We believe Hikma will be an excellent partner for us for Nimoral in the MENA region, which has a population of more than 380 million people or 6% of the world population.  We will immediately begin transferring our technology to Hikma to enable them to provide Nimoral to patients in MENA.”